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Smad7TGF-β1 is a prototypic proﬁbrotic cytokine and major driver of ﬁbrosis in the kidney and other organs. Induced
in high glucose-1 (IHG-1) is a mitochondrial protein which we have recently reported to be associated with
renal disease. IHG-1 ampliﬁes responses to TGF-β1 and regulates mitochondrial biogenesis by stabilising the
transcriptional co-activator peroxisome proliferator-activated receptor gamma coactivator-1-alpha. Here we
report that the mitochondrial localisation of IHG-1 is pivotal in the ampliﬁcation of TGF-β1 signalling. We
demonstrate that IHG-1 expression is associated with repression of the endogenous TGF-β1 inhibitor Smad7.
Intriguingly, expression of a non-mitochondrial deletion mutant of IHG-1 (Δmts-IHG-1) repressed TGF-β1
ﬁbrotic signalling in renal epithelial cells. In cells expressing Δmts-IHG-1 ﬁbrotic responses including CCN2/
connective tissue growth factor, ﬁbronectin and jagged-1 expression were reduced following stimulation
with TGF-β1. Δmts-IHG-1 modulation of TGF-β1 signalling was associated with increased Smad7 protein
expression. Δmts-IHG-1 modulated TGF-β1 activity by increasing Smad7 protein expression as it failed to inhibit
TGF-β1 transcriptional responses when endogenous Smad7 expression was knocked down. These data indicate
that mitochondria modulate TGF-β1 signal transduction and that IHG-1 is a key player in this modulation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Induced in high glucose-1 (IHG-1) also known as tRNA-histidine
guanylyltransferase 1-like (THG1L) is a mitochondrial associated protein
ﬁrst identiﬁed in a screen for genes associatedwith diabetic nephropathy
[1,2]. IHG-1 ampliﬁes responses to the major ﬁbrotic mediator trans-
forming growth factor (TGF)-β1 and regulates mitochondrial biogenesis
by stabilising the transcriptional co-activator peroxisome proliferator-
activated receptor gamma coactivator (PGC)-1α [3,4]. Increased activa-
tion of TGF-β1 is believed to be a pivotal mediator of disease develop-
ment in the diabetic kidney and in other ﬁbrotic disorders [5,6].
TGF-β1 initiates signalling through ligand dependent activation of a
complex of heteromeric transmembrane serine/threonine kinases,
consisting of type I and type II receptors. Upon phosphorylation by the
type II receptor, the type I receptor phosphorylates receptor-regulated
Smads (R-Smads) 2 and 3, the R-Smad complex with the common-
mediator Smad (Co-Smad) Smad4 and translocates to the nucleus
where they regulate gene transcription. Inhibitor Smads (I-Smads) 6
and 7 inhibit TGF-β signalling. Smad7 typically resides in the nucleus in
unstimulated cells and upon receptor activation translocates to thehy).
rights reserved.plasma membrane [7]. At the plasma membrane Smad7 may inhibit
TGF-β1 signal transduction by complexing with the TGF-β type I recep-
tor (TβR1) and preventing phosphorylation of R-Smads [8–10], by
recruiting WW-HECT-type E3 ubiquitin ligases (e.g. Smurf proteins) to
induce degradation of TGF-β type I receptor (TβR1) [11–14] and by facil-
itating dephosphorylation of TβR1 by phosphatases [15]. In the nucleus
Smad7 prevents the binding of functional R-Smad/Smad4 complexes
to target gene promoters [16]. Smad7 also associates with histone
deacetylases such as HDAC and SIRT1, and the acetyltransferase p300,
suggesting that Smad7may be involved in regulating the epigenetic sta-
tus of chromatin and therefore TGF-β1 target gene transcription [17–19].
Here we report that a non-mitochondrial deletion mutant of IHG-1 in-
creases Smad7 levels and inhibits TGFβ1 responses. Conversely expres-
sion of mitochondrial IHG-1 is associated with decreased Smad7 levels.
These data indicate that mitochondrial localisation of IHG-1 is pivotal
to its role in amplifying TGF-β1 signalling.
2. Materials and methods
2.1. Cell culture
HEK293T (ATCC, Middlesex, UK) was cultured in DMEM and MEM
respectively, containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin
1970 J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978and 1 mg/ml streptomycin — all from Invitrogen (Paisley, UK). Human
proximal tubular cells (HK-2) (ATCC, Middlesex, UK) were maintained
in low glucose DMEM (1 g/L glucose) (Invitrogen, Paisley, UK), 2 mM
glutamax (Invitrogen), 10 mM HEPES (Sigma-Aldrich, Dublin, Ireland),
10 ng/ml EGF (Sigma-Aldrich), 36 ng/ml hydrocortisone (Sigma-
Aldrich), ITS (10 μg/ml insulin; 5.5 μg/ml transferrin; 5 ng/ml sodium
selenite) (Sigma-Aldrich), 3 pg/ml triiodothyronine (Sigma-Aldrich),,
25 ng/ml prostaglandin E1 (Sigma-Aldrich), 100 U/ml penicillin and
1 mg/ml streptomycin (Invitrogen). Stably transduced cell lines have
been described previously [4].NM M NL N L L L
Sham       UUO
IHG-1
Smad7
34kDa
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A2.2. Lentivirus production, transfections and reporter gene assays
Δmts-IHG-1 (deletion of amino acids 9–22) was generated using
the QuickChange site-directed mutagenesis kit (Stratagene, Agilent
Technologies, Cork, Ireland). Plenti6/TGFβR1 was generated from
pRK5 TGFβR1 (T202D) Flag (Addgene (Cambridge MA) plasmid
1483)[20]. Recombinant lentivirus was produced by the transfection
of HEK293T cells with pCMV_R8.9, pMD.2G, and Plenti6/TGFβR1,
pGIPZ/Scr, pGipZ/Smad7 shRNAi (Thermo Fisher Scientiﬁc, Surrey,
UK), or empty vector control (EV) using a calcium phosphate transfec-
tion kit (Invitrogen). Transient transfection of cells with plasmids was
performed using either the Fugene 6 or Fugene HD reagent (Roche,
Dublin, Ireland) according to the manufacturer's instructions. The
cells were stimulated with TGF-β1 following 24 h in serum and supple-
ment free conditions, times and concentrations indicated in the ﬁgure
legends. Luciferase assays were performed using the Dual-Luciferase
Reporter Assay System (Promega, Mannheim, Germany). GAPDH 37kDa
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B2.3. RNA isolation and RT-PCR
Total RNA was extracted by using Trizol reagent (Invitrogen). 1 μg
of total RNA was reverse-transcribed using random primers and
SuperScript II (Invitrogen). RT-PCR was performed on an Applied
Biosystems 7900HT fast real-time PCR system using Taqman gene
speciﬁc assays (Applied Biosystems, Warrington, UK). Results were
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Fig. 1. IHG-1 decreases Smad7 expression. A. Altered expression in a 3-d UUOmodel. Total
protein extracts were prepared from non manipulated (NM) sham, M (manipulated)
(sham), L (ligated) NL (non-ligated) rat kidneys. Shown are representative western analy-
ses of these extracts probed for IHG-1, Smad7 andGAPDH. B. HK2 cells were co-transfected
with Smad 7-luc reporter and phRL-CMV plus or minus pcDNA6-IHG-1-V5, as indicated.
Fireﬂy luciferase activity normalised to Renilla luciferase activity was determined as direct-
ed by manufacturer (Promega). Where indicated, cells were stimulated with 5.0 ng/ml
TGF-β1 24 h after transfection. Luciferase activity was measured 24 h later. The results
shown are means ± s.e.m. of at least three independent experiments. Differences in
mean are signiﬁcant (P b 0.05). C. Cells were co-transfected with the 3TP-Lux reporter
and phRL-CMV plus or minus combinations of IHG-1-V5, Smad7 expression plasmids, as
indicated. Smad 7 signiﬁcantly inhibits IHG-1 enhancement of TGF-β1 induced luciferase
activity (P b 0.05).2.4. Immunoﬂuorescence analysis
Cells were plated onto 2 well chamber glass slides and allowed to
attach in serum containing medium. Cells were transfected with
tagged IHG-1 encoding plasmids (IHG-1-V5, Δmts-IHG-1-V5) using
Fugene 6 (Roche) and cultured in serum containing medium for
48 h. Cells were rinsed with PBS and ﬁxed in 3.7% paraformaldehyde
(Sigma) in PBS for 18 min. The cells were permeabilised in 0.1%
Triton in PBS on an orbital shaker for 10 min and then washed
twice for 10 min in PBS. Slides were blocked in 5% normal goat
serum (NGS) (Sigma) in PBS for 1 h at room temperature and incu-
bated with primary antibodies, anti-V5 (1/400 Invitrogen) and
anti-MnSOD (Stressgen Ann Arbour, Michigan, USA), (1/300), diluted
in 5% NGS in PBS for 1 h at room temperature. After rinsing with PBS,
slides were incubated with rabbit anti-mouse (for anti-V5) or goat
anti-rabbit antibody (for anti-MnSOD) conjugated to FITC (1/400,
Invitrogen) for 20 min at room temperature. Blocking and antibody
incubations were performed on an orbital shaker. Cells were mounted
in an antifade solution (Invitrogen). Secondary antibody only controls
were performed. The cells were ﬁxed and visualised with an Axioplan
2 Zeiss microscope and images were captured with a Carl Zeiss
AxioCam system and Axio Vision 3.0.6 software (Carl Zeiss, Inc.,
Thornwood, NY) or in some cases by laser confocal microscopy
(Zeiss SM 510) and Zeiss software using an ×63 oil immersion objec-
tive lens.2.5. SDS PAGE and immunoblotting
Whole-cell extracts were prepared in Cell Lytic Extraction buffer
(Sigma) with protease inhibitor mixture (Sigma) and phosphatase
inhibitor cocktail (Roche). Protein content was quantiﬁed and
normalised by using the Bradfordmethod (Bio-Rad, Hemel Hempstead,
UK). Proteins were separated by electrophoresis on SDS/PAGE gels.
Subcellular fractionation was performed using QproteomeNuclear Pro-
tein Kit (Qiagen, Crawley, UK). Antibodies: β-Actin (Sigma), Fibronec-
tin (BD Biosciences), Flag (Invitrogen), CTGF, GAPDH, Jagged-1, Jun-C,
Smad2, (Cell Signaling, Hertfordshire, UK), MnSOD (Stressgen),
pSmad2, Smad3 pSmad3 (Abcam, Cambridge, UK), Smad7 (Tebu
Biosciences, Peterborough, UK), and V5 (Invitrogen and Universal
Biologicals, Cambridge, UK). Densitometry was performed using ImageJ
software.2.6. Unilateral ureteral obstruction
The UUO model used was carried on male Wistar rats weighing
250–350 g (2–3 months of age) out under licence as describedpreviously
1971J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978[21] andwere handled either by the licencee or by licenced technicians in
accordance with institutional, ethical, and legal guidelines.
2.7. Statistical analysis
Results are expressed as mean ± s.e.m. and were analysed for
signiﬁcance by ANOVA. Statistical signiﬁcance was set at P ≤ 0.05.
3. Results
3.1. IHG-1 suppresses Smad7 expression
We have previously shown that IHG-1 mRNA expression is increased
by high extracellular glucose [1] and in the tubulointerstitium of diabeticMW G A C K V K V H D S L
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Fig. 2.Mitochondrial targeting sequence (mts) is required to localise IHG-1 to mitochondria
acids coloured red (9–22) were deleted from IHG-1 to generate Δmts-IHG-1 B. Cytoplasmi
been transfected with IHG-1-V5 or Δmts-IHG-1-V5. Shown is representative western analys
with anti-V5 and anti-MnSOD antibodies and analysed by immunoﬂuorescence microscopy
cells. Shown is western analysis of these extracts probed for Smad7 and MnSOD.nephropathy patients and in the UUO model of tubulointerstitial ﬁbrosis
[3]. We have proposed that IHG-1 contributes to ﬁbrotic renal disease as
it potentiates TGF-β1 signalling in HK-2 cells (renal proximal tubule cell
line [22]) leading to an increase in the expression of proteins associated
with ﬁbrosis i.e. proﬁbrotic mediator CCN2/connective tissue growth fac-
tor (CTGF) and extracellular matrix protein ﬁbronectin [3]. Increased
IHG-1 mRNA levels were detected following early injury in UUO and
when TIF was evident [3], IHG-1 protein expression was also increased
at 3 days post obstruction in the UUOmodel of kidney ﬁbrosis concomi-
tant with decreased Smad7 protein expression (Fig. 1A), indicating that
IHG-1 may enhance TGF-β proﬁbrotic responses by modulating Smad7
activity. TGF-β1 increases the expression of its own inhibitor Smad7 in a
well described negative feedback loop [23]. Recent research has demon-
strated a role for Smad7 in renal protection in vivo using models of bothA T I S I T L R R Y L R L
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Fig. 3. Δmts-IHG-1 increases Smad7 expression. A. Smad7 mRNA in EV or Δmts-
IHG-1 HK-2 cell lines were measured by qRT-PCR. B. Protein extracts were prepared
from cells in A ± TGF-β1 (5.0 ng/ml) stimulation for times indicated. Shown are
representative western analyses of these extracts probed for V5, Smad7 and
β-actin. Alterations in protein expression were measured using densitometric analy-
sis. The results shown are means ± s.e.m. of at least three independent experiments.
Differences in mean are signiﬁcant P b 0.05. C. EV or Δmts-IHG-1 HK-2 cell lines
were co-transfected with Smad 7-luc reporter and phRL-CMV. Luciferase assay
experimental analysis and presentation of results are as in Fig. 1B. Differences in
mean are signiﬁcant (P b 0.05).
1972 J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978ﬁbrosis [24] and DN [25]. Smad7 expression is reduced in renal epithelial
cells cultured in high extracellular glucose [26]. We investigated if IHG-1
ampliﬁed TGF-β1 responses by altering Smad7 expression. We report
that IHG-1 inhibited TGF- β1 mediated transcription from Smad7-luc
(Fig. 1B). TGF-β1 stimulation of the PAI promoter was inhibited when
Smad7 was overexpressed (Fig. 1C), as has previously been reported [8].
Smad7 also inhibited the ability of IHG-1 to enhance TGF-β1 induced
reporter gene expression (Fig. 1C). These data indicate that IHG-1
modulates TGF-β1 signalling responses by regulating Smad7 expression
levels.
3.2. Predicted N-terminal mitochondrial targeting sequence (mts) is
functional
We have previously shown that IHG-1 is localised to mitochondria
in mammalian cells and in rat kidneys [4] as determined by a combi-
nation of subcellular fractionation and immunocytochemistry. At the
amino terminal of human IHG-1 there is a predicted mitochondrial
targeting sequence (mts) [3]. To investigate the functionality of the
predicted mts amino acids 9–22 were deleted (Fig. 2A) and the
resulting mutant V5 tagged IHG-1 protein (Δmts-IHG-1-V5) was
expressed in HK-2 cells. In contrast to IHG-1-V5, Δmts-IHG-1-V5
did not co-localise with the mitochondrial marker MnSOD as judged
by western analysis (Fig. 2B). This observation was conﬁrmed by im-
munoﬂuorescence microscopy (Fig. 2C) indicating that the mts was
essential for mitochondrial localisation. These data indicate that the
mts is necessary for the localisation of IHG-1 to mitochondria.
Smad7 was found to be expressed in both cytoplasm and mitochon-
drial fractions prepared from HK-2 cells (Fig. 2D).
3.3. Δmts-IHG-1 increases Smad7 expression
To determine if IHG-1 mitochondrial localisation was important
for its ability to regulate Smad7 expression, we investigated the
expression of Smad7 in HK-2 cells expressing Δmts-IHG-1. Δmts-
IHG-1 increased the expression of Smad7 mRNA (Fig. 3A). Stimula-
tion with TGF-β1 did not alter Smad7 protein expression in HK-2
cells (Fig. 3B) similar to the ﬁndings in primary human renal cells
(HKCs) [27]. Δmts-IHG-1 resulted in an increased Smad7 protein
expression (Fig. 3B). Δmts-IHG-1 expression signiﬁcantly enhanced
transcription from a transfected Smad7 promoter reporter construct
(Fig. 3C). In the absence of TGF-β1 stimulation levels of reporter
gene expression were on average six-fold greater in HK-2 cells
expressing Δmts-IHG-1 (Fig. 2C). Following TGF-β1 stimulation
Δmts-IHG-1 doubled the levels of reporter gene expression (20-fold
vs 10-fold). These data indicate that Δmts-IHG-1 inhibits TGF-β1
signalling by increasing Smad7 expression.
3.4. Δmts-IHG-1 inhibits TGF-β1 proﬁbrotic responses
Reduced Smad7 expression in renal ﬁbrosis has been reported to
be associated with increased expression of ﬁbrotic markers such as
CTGF and ﬁbronectin [24,25]. In an animal model increasing Smad7
expression (by microbubble targeting to the kidney) was sufﬁcient
to rescue the ﬁbrotic phenotype [25]. Consistent with its ability to in-
crease expression Smad7 Δmts-IHG-1 was associated with the inhibi-
tion of TGF-β1-induced ﬁbrotic responses (CTGF and ﬁbronectin
protein expression) (Fig. 4A) in the HK-2 cell line. Δmts-IHG-1 also
decreased the expression levels of jagged-1, a Notch receptor ligand
[28] (Fig. 4A). Increased expression levels of jagged-1 have been
implicated in the pathophysiology of diabetic nephropathy and
renal ﬁbrosis [29].
We hypothesised that Δmts-IHG-1 induced Smad7 expression
may inhibit TGF-β1 activity by inhibiting TβR1 initiated cellular re-
sponses. Increased expression of TβR1 is a feature of tubulointerstitial
ﬁbrosis [30]. Overexpression of constitutively active TβR1 in HK-2cells led to an increased protein expression of ﬁbronectin, CTGF
and jagged-1, Δmts-IHG-1 inhibited TβR1 induced expression
levels of these proteins (Fig. 4B) further evidence that it could
inhibit proﬁbrotic responses initiated from TβR1 in renal epithelial
cells.
Furthermore Δmts-IHG-1-V5 reduced TGF-β1 mediated transcrip-
tion from a transfected TGF-β1-sensitive plasminogen activator in-
hibitor (PAI) promoter reporter construct (3TP-lux) (Fig. 4C). These
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Fig. 4. Δmts-IHG-1 inhibits TGF-β1 proﬁbrotic responses. A. Protein extracts were prepared from stably transfected empty vector (EV) and Δmts-IHG-1 HK-2 cells ± TGF-β1
(5.0 ng/ml) stimulation for times indicated. Shown are (i) representative western analyses of these extracts probed for V5, ﬁbronectin, CTGF, Jagged and β-actin. Alterations in
protein expression for (ii) ﬁbronectin, (iii) CTGF and (iv) Jagged were measured using densitometric analysis. The results shown are means ± s.e.m. of at least three independent
experiments. Differences in means are signiﬁcant P b 0.05. B. Protein extracts were prepared from EV and Δmts-IHG-1 cell lines that had been transiently transduced with lentivirus
overexpressing TβR1 (constitutively active (CA)) or EV control lentivirus. Experimental analysis and presentation of results are as in Fig. 4A. C. EV and Δmts-IHG-1 HK-2 cells ±
TGF-β1 (5.0 ng/ml) stimulation for times indicated co-transfected with the 3TP-lux reporter and phRL-CMV. Luciferase assay experimental analysis and presentation of results
are as in Fig. 1B. Differences in means are signiﬁcant (P b 0.05).
1973J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978data indicate that intriguingly IHG-1 must retain the potential to as-
sociate with mitochondria in order to amplify TGF-β1-induced tran-
scriptional responses, loss of mitochondrial localisation leads to
increases in Smad7 expression and inhibition of TGF-β1 induced
proﬁbrotic responses.3.5. Δmts-IHG-1 inhibits R-Smad mediated transcription but not
phosphorylation or translocation
However Δmts-IHG-1 did not alter phosphorylation levels of ei-
ther Smad2 or Smad3 following stimulation with TGF-β1 (Fig. 5A)
1974 J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978suggesting that Δmts-IHG-1 modulates TGF-β1 responses indepen-
dently of R-Smad phosphorylation. Δmts-IHG-1 did not alter shut-
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1975J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978SBE4-luc [31] minimal promoter reporter construct (Fig. 5D(i))
suggesting that Δmts-IHG-1 does not alter the ability of Smad3 to
bind to the Smad binding element (SBE) an 8 bp palindromic se-
quence (GTCTAGAC). The SBE is found in the human Smad7 promoter
and is necessary for the negative regulation of promoter activity by
Ski [32]. Mutation of the SBE increases Smad7 promoter basal activity
[32] but also results in the loss of response to TGF-β1 in mammalian
cell lines (i.e. HeLa, Mv1Lu/L17, and 293 cells). Δmts-IHG-1 signiﬁ-
cantly increased basal activity from the mutated Smad7 promoter
SBE-Smad7 [32] in renal epithelial cells which was unaltered follow-
ing TGF-β1 stimulation. Surprisingly TGF-β1 stimulation resulted in a
trend towards increased activity from the mutated Smad7 promoter
reporter in renal epithelial cells but this did not reach signiﬁcance
(Fig. 5D (ii)).3.6. Δmts-IHG-1 increases nuclear Smad7 expression and requires Smad7
to inhibit TGF-β1 responses
Δmts-IHG-1 was found to localise to both cytosolic and nuclear
fractions (Fig. 6A). Δmts-IHG-1 signiﬁcantly increased Smad 7 levels
in the nucleus (Fig. 6A). Nuclear Smad7 has been reported to inhibit
R-Smad transcriptional responses by preventing the formation of
functional R-Smad/Smad-4-DNA complexes [16]. These data indicate
that Δmts-IHG-1 inhibits TGF-β1 signalling by increasing Smad7
expression in the nucleus. To determine whether Smad7 expression
was necessary for Δmts-IHG-1 to modulate TGF-β1 mediated tran-
scriptional responses, we investigated the effects of short hairpin
microRNA (shRNAmir) induced loss of Smad7 expression on the
ability of Δmts-IHG-1 to inhibit TGF-β1 transcriptional responses.
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Fig. 6. Δmts-IHG-1 needs Smad7 to inhibit TGF-β responses. A. Cytosolic and nuclear ex-
tracts were prepared from from EV and Δmts-IHG-1 cell lines following stimulation with
5 ng/ml TGF-β1 for 60 min. Shown are western analyses of these extracts probed for
Smad7 and V5. Alterations in protein expression were measured using densitometric
analysis. The results shown are means ± s.e.m. of at least three independent experi-
ments. Differences in means in nuclear fractions are signiﬁcant (Tukey's Multiple
Comparison Test (P b 0.05)). B. Whole cell extracts were prepared from HK2 cells ex-
pressing short hairpin (sh) RNA interference constructs speciﬁc for Smad7 or a scrambled
construct (Scr). Shown is western analysis of these extracts probed with Smad7 and
GAPDH C. EV and Δmts-IHG-1 cells were cotransfected with 3TP-lux reporter and
phRL-CMV plus or minus smad7 shRNA or a scrambled construct (Scr). Luciferase assay
experimental analysis and presentation of results are as in Fig. 1C. Differences in mean
are signiﬁcant (P b 0.05).
1976 J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978Selective knockdown of Smad7 in HK-2 cells was achieved by
transient transfection with a plasmid that expressed Smad7 targeted
RNAmir (Fig. 6B). Δmts-IHG-1 over-expression signiﬁcantly inhibited
TGF-β1 mediated expression from 3TP-lux when transfected with a
plasmid expressing scrambled shRNAmir (Fig. 6C). In contrast in
cells transfected with shRNAmir targeted to Smad7, Δmts-IHG-1 no
longer had the ability to inhibit TGF-β1 activation of the 3TP-lux
promoter. Loss of Smad7 expression resulted in increased activation
of 3TP-Lux transcription as has been previously reported (Fig. 6C).
These data indicate that Δmts-IHG-1 inhibits transcriptional
responses to TGF-β1 by enhancing levels of Smad7.4. Discussion
We have previously described IHG-1 as an ampliﬁer of TGF-β1 in di-
abetic kidney disease [3]. Our current ﬁndings indicate that mitochon-
drial localisation of IHG-1 is pivotal to its role in TGF-β1 signalling as
deletion of the mitochondrial localisation signal of IHG-1(Δmts-IHG-1)
not only suppressed its ability to amplify TGF-β1 activity but also
inhibited TGF-β1 proﬁbrotic responses. These data indicate a regulatory
role for mitochondria in TGF-β1 signal transduction.
Mitochondrial dysfunction is a major contributor to hyperglycaemic-
induced kidney damage [33,34]. Oxidant stress resulting from increased
mitochondrial production of reactive oxygen species (ROS) is believed
to play a critical role in disease development [33] and disease associated
TGF-β1 activity [34]. Release of mitochondrial ROS is enhanced by the
activation of NADPH oxidases [35]. Mitochondrial associated IHG-1
may play a role linking oxidant stress to increased TGF-β1 signalling.
The role of mitochondria in energy metabolism, apoptosis and regu-
lation of calcium is well appreciated in the literature. However there is
an increasing awareness in the past decade of the role of mitochondria
in the integration and transmission of intracellular signal transduction
[36]. Mitochondrial signalling is involved in apoptotic and proliferative
pathways, nutrient sensing, inter-organelle communication and in the
responses of cells to metabolic transition and physiological stresses [36].
While increased ROS production is associated with the ampliﬁca-
tion of TGF-β1 responses to date mitochondria have not been described
to modulate Smad signalling yet TGF-β1, Smad4 and 5 have been de-
scribed to localise to mitochondria [37–39] while Smad6 and Smad7
have predicted mitochondrial targeting sequences [37]. Furthermore
connections between mitochondria, oxidative stress and TGFβ signal-
ling have been reported [40–42] while recent research on vascular
development suggests that TGFβ signalling pathway is dependent on
mitochondrial function [43]. Recently mitochondrial ROS generated at
complex III has been reported to be required for TGF-β-induced
gene expression (i.e. CTGF, Nox4 and α-SMA) in primary normal
human lung ﬁbroblasts [44]. Furthermore mitochondrial ROS ampliﬁes
TGF-β induced NOX4 (NADPH oxidase 4) expression important in
myoﬁbroblast differentiation [45]. Our results substantiate these ﬁnd-
ings as they indicate a key role for mitochondria in the regulation of
Smad7, an important modulator of TGF-β1 activity.
A classical SBE is found in the Smad7 promoter. This element in as-
sociation with transcription factors AP-1 and Sp1 is important in the
TGF-β1 induction of Smad7 [46]. Mutation of the SBE increases
Smad7 promoter basal activity [32] but also results in loss of response
to TGF-β1 stimulation in HeLa, Mv1Lu/L17, and 293 cells [32]. Maxi-
mal induction of the Smad7 promoter requires other transcription
factors (e.g. such as CBP/p300, FoxH1, TFE-3 (transcription factor
mE3), CBFA (PEBP2/core-binding factor A) and ATF2)[47] and
co-factors in addition to Smads [23] suggesting that IHG-1 is impor-
tant in the regulation of such factors possibly by increasing their
stability as we have previously described for the transcriptional
co-activator PGC-1α [4].
Both elevated TGF-β signalling and decreased Smad7 protein ex-
pression are often present in tissues where an uncontrolled ﬁbrotic
response occurs [47]. In kidney disease it has been reported that in-
creased Smad7 mRNA expression is associated with loss of Smad7
protein expression [30,48]. Similarly, TGF-β1 increased Smad7 tran-
scription in renal epithelial cells in this study but did not increase
Smad7 protein expression as previously reported for primary
human renal cells (HKCs) [27] where TGF-β1 stimulation decreased
Smad7 protein due to increased proteasomal degradation. TGF-β1
regulation of Smad7 protein is most likely context dependent as
Smad7 protein expression was increased in PC-3U cells by TGF-β1,
in these cells increased Smad7 expression resulted in apoptosis [49].
Increased expression of IHG-1 in renal cells most likely contributes
to ﬁbrosis by further reducing Smad7 protein expression by inhibiting
transcription.
1977J.B. Corcoran et al. / Biochimica et Biophysica Acta 1833 (2013) 1969–1978Δmts-IHG-1 increased expression of Smad7 mRNA, protein and
promoter activity and inhibited TGF-β1 induced transcription from
the PAI promoter and expression of ﬁbrotic proteins yet surprisingly
did not alter Smad phosphorylation or translocation. Similarly mito-
chondrial targeted antioxidants markedly attenuated TGF-β-induced
gene expression without affecting Smad phosphorylation or nuclear
translocation [44] indicating that Smad activity is regulated in the nu-
cleus. Δmts-IHG-1 was found both in the cytosol and the nucleus and
resulted in signiﬁcantly higher expression of Smad7 in the nucleus
but not in the cytosol. Given the increased levels of Smad7 in the nu-
cleus it is possible that Δmts-IHG-1 may retain Smad7 in the nucleus,
where it can act as a transcriptional coactivator/corepressor. It has
been shown that Smad7 has a nuclear coactivator function that is
independent of TGF-β signal transduction [50]. Smad7 interference
of R-Smad/Smad4-DNA association could account for the resultant
decrease in the transcription of TGF-β1 target genes. When Smad7
expression was knocked down by shRNA, Δmts-IHG-1 no longer
altered TGF-β1 transcriptional responses indicating that Δmts-IHG-1
mediates its antiﬁbrotic effects principally by increasing Smad7
expression. Smad 7 has been shown to have anti-ﬁbrotic actions
and there is good evidence to support the overexpression of Smad7
as a therapeutic approach to treat ﬁbrosis [25]. In an animal model
of diabetes, Smad7 expression (by microbubble targeting to the kid-
ney) was sufﬁcient to rescue the ﬁbrotic phenotype underlying how
important Smad7 may be in ﬁnding a robust therapeutic agent to
DN and to ﬁbrosis in general [25].
5. Conclusions
In summary our ﬁndings indicate a key role for mitochondria in
the modulation of TGF-β1 signal transduction. Expression of Δmts-
IHG-1 similar to inhibition of endogenous IHG-1 expression resulted
in an increased expression of Smad7. This increase in Smad7 expres-
sion resulted in reduced expression of ﬁbrotic associated proteins
CTGF, ﬁbronectin and jagged-1. Δmts-IHG-1 failed to inhibit TGF-β1
transcriptional responses when endogenous Smad7 expression was
reduced. Dysregulation of TGF-β signalling contributes to several dis-
ease processes (e.g. ﬁbrosis, cancer) making it a popular target for
drug development (e.g. small-molecule inhibitors, monoclonal anti-
bodies) [51]. However studies have shown that completely blocking
this pathway can lead to cancer, increased inﬂammation, autoimmu-
nity and cardiovascular disease [51]. Therefore it would be more
desirable to decrease excessive levels of TGF-β activity rather than
to totally inhibit signal transduction. Smad 7 has been shown to
attenuate TGF-β activity and has good potential to treat anti-ﬁbrotic
disease [25,51]. Δmts-IHG-1 offers the advantage of stimulating en-
dogenous Smad7 expression and thereby readdressing the imbalance
found in kidney ﬁbrosis and perhaps other ﬁbrotic diseases. Although
a smaller protein than Smad7, the molecular weight of Δmts-IHG-1
still poses difﬁculties for delivery. Our future aim is to determine
the regions within Δmts-IHG-1 that are necessary to induce the
expression of Smad7 and thus develop a more readily deliverable
therapeutic. We have renamed Δmts-IHG-1 as ITA1 (inhibitor of
TGF-β1 activity 1) and propose ITA1 as a novel biotherapeutic for
the treatment of ﬁbrotic renal disease.
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